Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma

Clinical Cancer Research

Volumn 4, Issue 3, 1998, Pages 619-627

  Eton, Omar ^a,d   Kharkevitch, Dmitri D ^a   Gianan, Mary Ann ^a   Ross, Merrick I ^a   Itoh, Kyogo ^b   Pride, Michael W ^a   Donawho, Cherrie ^a   Buzaid, Antonio C ^a   Mansfield, Paul F ^a   Lee, Jeffrey E ^a   Legha, Sewa S ^a   Plager, Carl ^a   Papadopoulos, Nicholas E ^a   Bedikian, Agop Y ^a   Benjamin, Robert S ^a   Balch, Charles M ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHORYL LIPID A;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; INTRADERMAL DRUG ADMINISTRATION; MALE; MELANOMA; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; SKIN METASTASIS; ULTRAVIOLET B RADIATION;

EID: 15144342462     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Hewitt, H., Blake, E., and Walder, A. A critique of the evidence for active host defense against cancer based on personal studies of 27 murine tumors of spontaneous origin. Br. J. Cancer, 33: 241-259, 1976.
2. Gross, L. Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Res., 3: 326-333, 1943.
3. Prehn, R. T., and Main, J. M. Immunity to methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst., 18: 769-778, 1957.
4. Klein, G., Sjogren, H., Klein, E., and Hellstrom, H. E. Demonstration of resistance against methylcholanthrene induced sarcomas in the primary autochthonous host. Cancer Res., 20: 1561-1572, 1960.
5. Kripke, M. L. Antigenicity of murine skin tumors induced by ultra-violet light. J. Natl. Cancer Inst., 53: 1333-1336, 1974.
6. Jager, E., Ringhoffer, M., Altmannsberger, M., Arand, M., Karbach, J., Jager, D., Ocsch, F., and Knuth, A. Immunoselection in vivo: loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Abstracts S21 and M16, Cancer Vaccines, Cancer Research Institute (New York), 1996.
7. Suzuki, T., Tahara, H., Narula, S., Moore, K. W., Robbins, P. D., and Lotze, M. T. Viral interleukin 10 (IL-10), the human herpes virus 4 cellular IL-10 homologue, induces local anergy to allogeneic and syngeneic tumors. J. Exp. Med., 182: 477-486, 1995.
8. Mizoguchi, H., O'Shea, J. J., Longo, D. L., Loeffler, C. M., McVicar, D. W., and Ochoa, A. C. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science (Washington DC), 258: 1795-1798, 1992.
9. Hahne, M., Rimoldi, D., Schroter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., Cerottini, J., and Tschopp, J. Melanoma cell expression of Fas (Apo1/ CD95) ligand: implications for tumor immune escape. Science (Washington DC), 274: 1363-1366, 1996.
10. Wiertz, E. J., Tortorella, D., Bogyo M., Yu, J., Mothes, W., Jones, T. R., Rapoport, T. A., and Ploegh, H. L. Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature (Lond.), 384: 432-438, 1996.
11. Jain, R. K. Barriers to drug delivery in solid tumors. Sci. Am., 271: 58-65, 1994.
12. Cheson, B. D., Phillips, P. H., and Sznol, M. Trials using tumor vaccines. Oncology (Basel), 11: 81-90, 1997.
13. Berd, D., Maguire, H. C., Jr., McCue, P., and Mastrangelo, M. J. Treatment of metastatic melanoma with an autologous tumor cell vaccine: clinical and immunologic results in 64 patients. J. Clin. Oncol., 8: 1858-1867, 1990.
14. Morton, D. L., Foshag, L. J., Hoon, D. S., Nizze, J. A., Wanek, L. A., Chang, C., Davtyan, D. G., Gupta, R. K., Elashoff, R., and Irie, R. F. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann. Surg., 26: 463-482, 1992.
15. Leong, S. P. L., Enders-Zohr, P., Zhou, Y. M., Allen, R. W., Jr., Saagebiel, A. B., Glassberg, A. B., and Hayes, F. A. Active specific immunotherapy with GM-CSF as an adjuvant to autologous melanoma vaccine in metastatic melanoma. Proc. Am. Soc. Clin, Oncol. Annu. Meet., 15: 437, 1996.
16. Hosteller, L. W., Ananthaswamy, H. N., and Kripke, M. L. Generation of tumor-specific transplantation antigens by UV radiation can occur independently of neoplastic transformation. J. Immunol., 137: 2721-2725, 1986.
17. Hostetler, L. W., and Kripke, M. L. Proportion of antigenic variants induced by in vitro UV irradiation differs in clones derived from a single tumor. J. Immunol., 140: 666-670, 1988.
18. Hosteller, L. W., Romerdahl, C. A., and Kripke, M. L. Specificity of antigens on UV radiation-induced antigenic tumor cell variants measured in vitro and in vivo. Cancer Res., 49: 1207-1213, 1989.
19. Umezu, Y., Augustus, L. B., Seito, D., Hayakawa, K., Ross, M. I., Eton, O., Swanson, D. A., and Itoh, K. Increase in the ability of human cancer cells to induce cytotoxic T lymphocytes by ultraviolet irradiation. Cancer Immunol. Immunother., 37: 392-399, 1993.
20. Pride, M. L., Donawho, C. K., and Kripke, M. L. Active specific immunotherapy using UVB-irradiated whole melanoma cell vaccine. Abstract 5211, 9th International Congress of Immunology (San Francisco), 1995.
21. Pride, M. L., Donawho, C. K., and Kripke, M. L. UVB irradiation of tumor cells enhances the immunogenicity of melanoma cell vaccines by augmenting cell surface expression of MHC class I and II and B7-1. Proc. Am. Assoc. Cancer Res., 38: 630, 1997.
22. Shinomiya, Y., Harada, M., Kurosawa, S., Okamoto, T., Terao, H., Matsuzaki, G., Shirakusa, T., and Nomoto, K. Anti-metastatic activity induced by the in vivo activation of purified protein derivative (PPD)-recognizing Th1 type CD4+ T cells. Immunobiology, 193: 439-455, 1995.
23. Schultz, N., Oratz, R., Chen, D., Zeleniuch-Jacquotte, A., Abeles, G., and Bystryn, J. C. Effect of DETOX as an adjuvant for melanoma vaccine. Vaccine, 13: 503-508, 1995.
24. Mitchell, M. S., Harel, W., Kempf, R. A., Hu, E., Kan-Mitchell, J., Boswell, W. D., Dean, G., and Stevenson, L. Active-specific immunotherapy for melanoma. J. Clin. Oncol., 8: 856-869, 1990.
25. Itoh, K., Platsoucas, C. D., and Balch, C. M. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrates of human metastatic melanoma. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. J. Exp. Med., 168: 1419-1441, 1988.
26. Itoh, K., Tilden, A. B., and Balch, C. M. Interleukin-2 activation of cytotoxic T lymphocytes infiltrating into human metastatic melanomas. Cancer Res., 46: 3011-3017, 1986.
27. Mulder, W. M., Koenen, H., van de Muysenberg, A. J., Bloemena, E., Wagstaff, J., and Scheper, R. J. Reduced expression of distinct T-cell CD molecules by collagenase/DNase treatment. Cancer Immunol. Immunother., 38: 253-258, 1994.
28. Abuzakouk, M., Feighery, C., and O'Farrelly, C. Collagenase and dispase enzymes disrupt lymphocyte surface molecules. J. Immunol. Methods, 194: 211-216, 1996.
29. Berd, D., Herlyn, M., Koprowski, H., and Mastrangelo, M. J. Flow cytometric determination of the frequency and heterogeneity of expression of human melanoma-associated antigens. Cancer Res., 49: 6840-6844, 1989.
30. Bystryn, J. C., Jacobson, S., Harris, M. N., Roses, D. F., Speyer, J. L., and Levin, M. Preparation and characterization of a human polyvalent melanoma antigen vaccine. J. Biol. Response Modif., 5: 211-224, 1986.
31. Mather, J. P., and Sato, G. H. The growth of mouse melanoma cells in hormone supplemented serum-free medium. Exp. Cell Res., 120: 199-200, 1979.
32. Simon, R. Optimal two-stage designs for Phase II clinical trials. Control. Clin. Trials, 10: 1-10, 1989.
33. Eton, O., Legha, S. S., Moon, T. E., Papadopoulos, N. E., Plager, C., Burgess, A. M., Bedikian, A. Y., Buzaid, A. C., Ring, S., Dong, Q., Glassman, A. B., Balch, C. M., and Benjamin, R. S. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J. Clin. Oncol., in press, 1998.
34. Sirott, M. N., Bajorin, D. F., Wong, G. Y., Tao, Y., Chapman, P. B., Templeton, M. A., and Houghton, A. N. Prognostic factors in patients with metastatic malignant melanoma: a multivariate analysis. Cancer (Phila.), 72: 3091-3098, 1993.
35. Anderson, J. R., Crowley, J. J., and Propert, K. J. Interpretation of survival data in clinical trials. Oncology, 5: 104-114, 1991.
36. Zhu, H., Melder, R. J., Baxter, L. T., and Jain, R. K. Physiologically based kinetic model of effector cell biodistribution in mammals: implications for adoptive immunotherapy. Cancer Res., 56: 3771-3781, 1996.
37. Economou, J. S., Belldegrun, A. S., Glaspy, J., Toloza, E. M., Figlin, R., Hobbs, J., Meldon, N., Kaboo, R., Tso, C. L., Miller, A., La, R., McBride, W., and Moen, R. C. In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial. J. Clin. Invest., 97: 515-521, 1996.
38. Suto, R., and Srivastava, P. K. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science (Washington DC), 269: 1585-1588, 1995.